Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

Pfizer

Overview

The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Study Type

OBSERVATIONAL

Conditions

Abscess, Intra-Abdominal Cholecystitis Wound Infections Peritonitis Appendicitis

Interventions

CP-75385-02 Cefoperazone/sulbactamDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patient of age 18 years or older. * Patient with intraabdominal/hepatobiliary infection.? Exclusion Criteria: * Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.